Silo Pharma, Inc. Files 8-K: Material Agreement, Equity Sales

TL;DR

Silo Pharma signed a big deal and sold some stock on 9/29/25.

AI Summary

On September 29, 2025, Silo Pharma, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate activity for Silo Pharma, Inc., including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks.

Key Players & Entities

• Silo Pharma, Inc. (company) — Registrant
• September 29, 2025 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 001-41512 (commission_file_number) — SEC File Number
• 677 N. Washington Blvd (address) — Business and Mail Address

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
• $0.875 — "Common Stock") at a purchase price of $0.875 per Share (the "Offering"). The Shares
• $0.75 — The Warrants have an exercise price of $0.75 per share, are exercisable immediately
• $2.5 m — ds from the Offering were approximately $2.5 million, prior to deducting placement age
• $1.0938 — 25% of the offering price per Share, or $1.0938 per share. The Placement Agent Warrants
• $25,000 — agreed to reimburse the Placement Agent $25,000 for non-accountable expenses, $50,000 f
• $50,000 — t $25,000 for non-accountable expenses, $50,000 for legal expenses and other out-of-poc
• $15,950 — es and other out-of-pocket expenses and $15,950 for clearing fees. Pursuant to the ter

Filing Documents

• ea0259464-8k_silo.htm (8-K) — 38KB
• ea025946401ex4-1_silo.htm (EX-4.1) — 92KB
• ea025946401ex4-2_silo.htm (EX-4.2) — 93KB
• ea025946401ex5-1_silo.htm (EX-5.1) — 13KB
• ea025946401ex10-1_silo.htm (EX-10.1) — 235KB
• ea025946401ex99-1_silo.htm (EX-99.1) — 10KB
• ea025946401ex99-2_silo.htm (EX-99.2) — 9KB
• ex5-1_001.jpg (GRAPHIC) — 10KB
• ex99-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-25-094711.txt ( ) — 793KB
• silo-20250929.xsd (EX-101.SCH) — 3KB
• silo-20250929_lab.xml (EX-101.LAB) — 33KB
• silo-20250929_pre.xml (EX-101.PRE) — 22KB
• ea0259464-8k_silo_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On September 29, 2025, Silo Pharma, Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain institutional investors, pursuant to which the Company agreed to sell to such investors 2,857,143 shares (the "Shares") of common stock, par value $0.0001 per share of the Company (the "Common Stock") at a purchase price of $0.875 per Share (the "Offering"). The Shares were offered by the Company pursuant to its shelf registration statement on Form S-3 (File No. 333-276658), which was declared effective by the Securities and Exchange Commission on January 30, 2024. Concurrently with the sale of the Shares pursuant to the Purchase Agreement in a private placement, for each Share purchased by the investors, such investors received from the Company an unregistered warrant (the "Warrants") to purchase one share of Common Stock (the "Warrant Shares"). The Warrants have an exercise price of $0.75 per share, are exercisable immediately upon issuance and will expire five years from the effective date of a registration The closing of the sales of these securities under the Purchase Agreement took place on October 1, 2025. The gross proceeds from the Offering were approximately $2.5 million, prior to deducting placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for working capital and other general corporate purposes. The Warrants and the Warrant Shares were sold without registration under the Securities Act of 1933 (the "Securities Act") in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. The representation

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference. The Warrants and the Placement Agent Warrants and the shares issuable upon exercise of the Warrants and Placement Agent Warrants have not been registered under the Securities Act, or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.

01 Other Events

Item 8.01 Other Events. On September 30, 2025, the Company issued a press release announcing the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. On October 1, 2025, the Company issued a press release announcing the closing of the Offering. A copy of the press release is furnished as Exhibit 99.2 to this Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 4.1 Form of Warrant 4.2 Form of Placement Agent Warrant 5.1 Opinion of Sheppard, Mullin, Richter & Hampton LLP 10.1* Form of Securities Purchase Agreement 99.1 Press release of Silo Pharma, Inc. dated September 30, 2025 99.2 Press release of Silo Pharma, Inc. dated October 1, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of Regulation S-K. The Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request -2-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: October 1, 2025 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR